Find a Tender
complete
Official procurement procedure
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
No classification published
Location not published
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS England: "NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | NHS England | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: NHS England
Market Analytics
Derived from OCDS awards & bid statistics
Published history for NHS England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Competition Density
22.8Bids / Report
Supplier ConcentrationModerate Concentration
Anna FreudTop vendor: 29.6% of attributable valuePayment Terms
Check noticePublished terms
Coverage: 859 active published awards; 13 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Historical Awarded Suppliers With This Authority:
| Supplier Name | Historic Awards | Attributable GBP Value |
|---|---|---|
| Anna Freud | 1 win | £5,862,540 |
| Anglia Ruskin University | 1 win | £4,809,159 |
| NHS Shared Business Services Limited | 1 win | £4,393,727 |
| Pearson Professional Assessments Limited | 1 win | £4,374,320 |
| Timewise Foundation CIC | 1 win | £166,667 |
Procedure terms
Contracting AuthorityNHS England | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSFramework | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published6 Oct 2025, 12:40 BST | Last source update6 Oct 2025, 12:40 BST | Recurring procurementNot published |
ClassificationNot published | ||
Delivery areaLocation not published | ||
OCIDocds-h6vhtk-055064 | ||
What is being bought
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
Offer reference number: CM/PHS/25/5728
Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.
Potential periods of call-offs under the framework agreement:
CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:
7NAT (National) 01/12/2025 to 31/05/2027 (18 months)
CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg:
NOFE: (North of England) 01/12/2025 to 31/05/2027 (18 months)
SOFE: (South of England) 01/12/2025 to 31/05/2027 (18 months)
MAE: (Midlands and East) 01/12/2025 to 31/05/2027 (18 months)
LNW: (London) 01/12/2025 to 31/05/2027 (18 months)
Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England
Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of;
• neovascular (wet) age-related macular degeneration (AMD)
• visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
• proliferative diabetic retinopathy (PDR)
• visual impairment due to diabetic macular oedema (DME)
• visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy
• vision impairment associated with chronic diabetic macular oedema, (DME)
• visual impairment due to myopic choroidal neovascularisation (myopic CNV)
• retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease
• inflammation of the posterior segment of the eye presenting as non-infectious uveitis
• prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye
What changed
From the official release history
- Official notice release published
6 Oct 2025, 12:40 BST - Buyer information updated
6 Oct 2025, 12:40 BST - Status changed to complete
1 Aug 2025, 11:49 BST - Official notice release published
1 Aug 2025, 11:49 BST - Buyer information updated
1 Aug 2025, 11:49 BST
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcompletePublished valueNot publishedThe source published no individual title or description for this lot.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
6 Oct 2025, 12:40 BST - Award active
Not published · Not published - Award active
Not published · Not published - Contract active
Signed 22 Sept 2025, 00:00 BST · £688,834,174 - Contract active
Signed 22 Sept 2025, 00:00 BST · £782,917,972
Commercial outcome and competition
Awards ABBVIE LTD, Alimera Sciences, BAYER PUBLIC LIMITED COMPANY, BIOGEN IDEC LIMITED, NOVARTIS PHARMACEUTICALS UK LIMITED, Orion Pharma (UK) Ltd, Outlook Therapeutics, Inc., ROCHE PRODUCTS LIMITED, TEVA UK LIMITED, THORNTON & ROSS LIMITED Not published · Not published · active BAYER PLC, BIOSIMILAR COLLABORATIONS IRELAND LIMITED, Celltrion Healthcare, MDBIOLOGICS LTD, SANDOZ LIMITED Not published · Not published · active |
Contracts Lot 1 - CM/PHS/25/5728/01 £688,834,174 · signed 22 Sept 2025, 00:00 BST · active Contract period: 1 Dec 2025, 00:00 GMT — 31 May 2027, 23:59 BST Lot 2 - CM/PHS/25/5728/02 £782,917,972 · signed 22 Sept 2025, 00:00 BST · active Contract period: 1 Dec 2025, 00:00 GMT — 31 May 2027, 23:59 BST |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
NHS England
Contracting authority GB-PPON-PDPT-3135-BWWYDocuments (1)
Official links; attachments are not copied
Related procedures (0)
No related procedures published